Fosun expects 1H profit attributable to owners at RMB 1.5 billion-RMB 1.8 billionPUBT·1 day ago, 04:33 AM02196-6.00%00656+7.88%
Nomura Cuts HENGRUI PHARMA TP to HKD82.18, Lowers FY2026 Revenue and Profit ForecastsAASTOCKS News·Jul 26 at 10:29 PM01276-1.54%600276+1.41%
Hengrui Pharma Wins First China Approval for Home-Grown Long-Acting Insulin AnalogTip Ranks·22 hours ago01276-1.54%600276+1.41%
Hengrui Wins NMPA Nod to Move Cervical Cancer Combo to First-Line UseTip Ranks·Jul 23 at 07:37 AM01276-1.54%600276+1.41%
Hengrui Pharma wins China approval for camrelizumab-famitinib combo as 1L cervical cancer treatmentPUBT·Jul 23 at 07:32 AM01276-1.54%600276+1.41%
As weight-loss drug orders surge, global funds pile into China’s WuXi AppTecSCMP·Jul 24 at 05:39 AM02359-0.57%603259-0.81%
From confidence to capital: Positioning biotech for the next growth cyclebiopharmadive·2 days ago, 10:38 AMLABU-4.04%LABD+3.70%
China's 1H25 Innovative Drug Out-Licensing Deal Value Exceeds USD100 Billion, Hitting New HighAASTOCKS News·Jul 20 at 01:00 AM510660-0.93%159992-2.35%
WuXi AppTec joins FTSE4Good Index Series for fourth straight yearPUBT·Jul 21 at 06:54 PM02359-0.57%603259-0.81%
IDEAYA shares ESMO 2026 data updates for darovasertib trials in uveal melanomaPUBT·Jul 17 at 08:00 AMIDYA-1.58%01276-1.54%
Chinese biotech overtakes AI as emerging-market growth tradeBusinesstimes News·Jul 26 at 10:14 PM300765-5.26%AZN+0.48%
China's Humanoid Robot Products Exceed 400 Models, Accounting for Over Half of Global TotalAASTOCKS News·Jul 20 at 01:00 AM513060-2.05%159859-1.30%
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Receives a Buy from Morgan StanleyTip Ranks·Jul 17 at 07:27 PM01276-1.54%600276+1.41%
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs | IDYA Stock NewsStockTitan·Jul 17 at 12:00 AMIDYA-1.58%600276+1.41%
Virax Biolabs signs Fosun Diagnostics supply deal for ImmuneSelect in six Southeast Asian marketsPUBT·Jul 16 at 06:33 AMVRAX+1.38%02196-6.00%
